Haupt Pharma AG
Haupt Pharma AG, a leading contract development and manufacturing organisation (CDMO), is headquartered in Germany and operates extensively across Europe. Founded in 1994, the company has established itself as a key player in the pharmaceutical industry, specialising in the development and production of solid dosage forms, sterile products, and complex formulations. With a commitment to quality and innovation, Haupt Pharma AG offers a comprehensive range of services, including formulation development, analytical services, and regulatory support. Their state-of-the-art facilities and adherence to stringent quality standards set them apart in the competitive landscape. Recognised for their expertise and reliability, Haupt Pharma AG has achieved significant milestones, including successful partnerships with major pharmaceutical companies. Their dedication to excellence positions them as a trusted partner in the global healthcare market.
DitchCarbon Score
How does Haupt Pharma AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Haupt Pharma AG's score of 20 is lower than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Haupt Pharma AG, headquartered in Germany, currently does not report specific carbon emissions data, as no figures are available. The company is identified as a merged entity and may inherit emissions data from its corporate family, but no specific details have been provided regarding this cascade. In terms of climate commitments, Haupt Pharma AG has not outlined any reduction targets or initiatives, nor does it participate in recognised frameworks such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). This lack of publicly available information suggests that the company may still be in the early stages of developing its climate strategy. As the pharmaceutical industry increasingly focuses on sustainability, it is essential for Haupt Pharma AG to establish clear emissions reduction goals and engage in climate initiatives to align with industry standards and expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | |
|---|---|---|
| Scope 1 | 211,050 | 000,000 |
| Scope 2 | 2,464,370 | 0,000,000 |
| Scope 3 | 777,010 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Haupt Pharma AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
